An Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in both ERT Experienced and ERT Naive Pediatric Subjects with Infantile- Onset Pompe Disease Aged 0 < 18